← Back to headlines
ResMed Downgraded by Morgan Stanley Amid Philips Re-entry and GLP-1 Headwinds
ResMed's stock has been downgraded by Morgan Stanley, citing concerns over Philips' re-entry into the market and potential headwinds from GLP-1 drugs.
17 Jun, 12:49 — 17 Jun, 12:49
Sources
Showing 1 of 1 sources
